|
End-of-day quote
Palestine Exchange
2026-08-19
|
5-day change | 1st Jan Change | ||
| 3.600 USD | +2.86% |
|
0.00% | +56.52% |
| 08-13 | Jerusalem Pharmaceuticals Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-30 | Jerusalem Pharmaceuticals Announces Board Changes | CI |
| Market Cap | 130M 111M 104M 95.01M 178M 12.4B 181M 1.23B 478M 6.23B 487M 476M 20.59B | P/E 2024 |
13.7x | P/E 2025 | 8.13x |
|---|---|---|---|---|---|
| Enterprise Value | 119M 102M 95.06M 87.03M 163M 11.36B 166M 1.12B 438M 5.7B 446M 436M 18.86B | EV / Sales 2024 |
1.47x | EV / Sales 2025 | 1.47x |
| Free-Float |
35.74% | Yield 2024 |
2.09% | Yield 2025 | 3.26% |
| 1 day | +2.86% | ||
| Current month | -4.00% | ||
| 1 month | -4.00% | ||
| 3 months | -2.96% | ||
| 6 months | +55.51% | ||
| Current year | +56.52% |
| 1 week | 3.5 | 3.6 | |
| 1 month | 3.5 | 3.75 | |
| Current year | 2.28 | 4 | |
| 1 year | 1.9 | 4 | |
| 3 years | 1.74 | 4 | |
| 5 years | 1.32 | 4 | |
| 10 years | 0.8 | 4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2013-06-30 | |
Mohammed Natour
DFI | Director of Finance/CFO | - | 2020-02-29 |
Lina Masrouji
CTO | Chief Tech/Sci/R&D Officer | - | 1988-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 91 | - | |
Nidal Kamal
BRD | Director/Board Member | - | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.86% | 0.00% | +73.49% | +88.48% | 130M | ||
| -0.08% | -1.53% | +16.49% | +67.63% | 47.74B | ||
| -3.21% | -1.93% | +51.06% | +125.79% | 41.7B | ||
| -0.40% | -1.82% | -7.37% | +15.84% | 12.14B | ||
| +1.11% | -4.05% | +13.90% | +72.88% | 11.55B | ||
| 0.00% | 0.00% | +30.00% | +147.62% | 9.18B | ||
| -0.39% | +0.62% | +19.93% | +39.54% | 7.54B | ||
| -1.35% | +1.26% | +44.30% | -11.69% | 7.35B | ||
| -0.64% | -0.09% | +20.47% | +202.52% | 6.88B | ||
| -5.36% | -8.72% | -34.95% | +17.39% | 5.72B | ||
| Average | -0.75% | -1.29% | +22.73% | +76.60% | 14.99B | |
| Weighted average by Cap. | -1.18% | -0.77% | +24.60% | +83.90% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 39.82M 34.1M 31.89M 29.19M 54.81M 3.81B 55.55M 377M 147M 1.91B 150M 146M 6.33B | 48.95M 41.91M 39.2M 35.88M 67.36M 4.68B 68.27M 463M 181M 2.35B 184M 180M 7.78B |
| Net income | 5.04M 4.31M 4.03M 3.69M 6.93M 482M 7.03M 47.67M 18.58M 242M 18.91M 18.5M 800M | 10.18M 8.72M 8.16M 7.47M 14.01M 974M 14.2M 96.35M 37.56M 489M 38.23M 37.4M 1.62B |
| Net Debt | -10.32M -8.84M -8.27M -7.57M -14.21M -988M -14.4M -97.67M -38.07M -496M -38.75M -37.91M -1.64B | -10.9M -9.33M -8.73M -7.99M -15M -1.04B -15.2M -103M -40.19M -523M -40.91M -40.02M -1.73B |
Employees
595
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-19 | US$3.600 | +2.86% | 1,200 |
| 26-08-18 | US$3.500 | -2.78% | 5,437 |
| 26-08-17 | US$3.600 | 0.00% | 65 |
| 26-08-13 | US$3.600 | -1.37% | 2,286 |
- Stock Market
- Stocks
- JPH Stock
Select your edition
All financial news and data tailored to specific country editions
















